MA方案与ID-Ara-C方案治疗难治性及复发性急性髓细胞性白血病疗效观察  

Results of MA and IDAraC chemotherapy in patients with refractory of relapsed acute myelogenous leukemia

作　　者：赖永榕[1] 彭志刚[1] 罗军 周建生 卢玉英 

机构地区：[1]广西医科大学第一附属医院

出　　处：《临床内科杂志》1999年第1期33-34,共2页Journal of Clinical Internal Medicine

摘　　要：目的探讨难治、复发性白血病的治疗方法。方法用ＭＡ方案和ＩＤ－Ａｒａ－Ｃ方案治疗３４例成人难治性及复发性急性髓细胞性白血病（ＡＭＬ）。结果完全缓解（ＣＲ）率为３２．４％，有效率４１．２％；其中难治组ＣＲ率为２１．４％，复发组ＣＲ率为４０％（Ｐ＞０．０５）；ＭＡ方案组ＣＲ率为３７．５％；ＩＤ－Ａｒａ－Ｃ方案组ＣＲ率为２０％（Ｐ＞０．０５）。随访观察，取得ＣＲ的１１例病人，中位ＣＲ期为１２月（３～３２个月）；存活３年以上者１例（２．９％）。结论ＭＡ方案及ＩＤ－Ａｒａ－Ｃ方案对诱导成人难治及复发性ＡＭＬ的临床缓解有一定效果，但持续ＣＲ时间短，长期预后差，能长期生存的机会极微，仍需探索更好的治疗方法。Objective To study the clinical treatment methods of refractory or relapsed acute leukemia. Methods 34 patients with refractory or relapsed acute myelogenous leukemia(AML)were treated by MA and IDAraC chemotherapy. Results The complete remission(CR)rate was 32.4%(11/34).The CR rate was 21.4% in the refractory patients and 40% in the relapsed patients(P>005).The CR rate was 37.5% in the MA groap and 20% in the IDAraC group(P>005).The medium duration of CR was 12(332)months.Only one(2.9%)patient survived more than three years. Conclusion The results showed that MA and IDAraC chemotherapy are effective methods for inducing CR in patients with refractory or relapsed AML.But the duration of CR was short,the longterm prognosis was poor,and the chances of the longterm survival in these patients were very rarely.

关 键 词：米托恩醌 阿糖胞苷 白血病 AML 药物疗法 

分 类 号：R733.710.5[医药卫生—肿瘤]